Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

This study has been completed.

Sponsored by:	Asociación para Evitar la Ceguera en México
Information provided by:	Asociación para Evitar la Ceguera en México
ClinicalTrials.gov Identifier:	NCT00407121

Purpose

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Condition	Intervention	Phase
Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis	Drug: Bevacizumab Procedure: Intravitreal Injection of Bevacizumab	Phase III

Drug Information available for: Bevacizumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Further study details as provided by Asociación para Evitar la Ceguera en México:

Primary Outcome Measures:

Best corrected visual acuity
Retinal thickness by OCT
Leakage in Fluorescein angiogram

Study Start Date:	August 2006
Estimated Study Completion Date:	November 2006

Eligibility

Ages Eligible for Study:	25 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Clinical Diagnose
Patient Consent
Chronic stage of inflammation

Exclusion Criteria:

only eye
age lower than 30 yo.
Systemic condition

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00407121

Locations

Mexico, Distrito Federal
Asociacion para Evitar la Ceguera en Mexico
Mexico, Distrito Federal, Mexico, 04030

Sponsors and Collaborators

Asociación para Evitar la Ceguera en México

Investigators

Principal Investigator:	Veronica Kon-Jara, MD	Asociacion para Evitar la Ceguera en Mexico
Study Chair:	LuzElena Concha-Del Rio, MD	Asociacion para Evitar la Ceguera en Mexico

More Information

Study ID Numbers:	APEC-0025
Study First Received:	December 1, 2006
Last Updated:	December 1, 2006
ClinicalTrials.gov Identifier:	NCT00407121
Health Authority:	National Institute of Public Health: Health Secretariat

Keywords provided by Asociación para Evitar la Ceguera en México:

Neovascular Membrane
Uveitis
Bevacizumab

Study placed in the following topic categories:

Panuveitis
Uveomeningoencephalitic Syndrome
Autoimmune Diseases
Uveitis, Posterior
Eye Diseases
Choroid Diseases
Central Nervous System Diseases
Bevacizumab

Inflammation
Multifocal choroiditis
Central Nervous System Infections
Uveitis
Choroiditis
Vogt-Koyanagi-Harada syndrome
Autoimmune Diseases of the Nervous System

Additional relevant MeSH terms:

Uveal Diseases
Immune System Diseases
Antineoplastic Agents
Therapeutic Uses
Growth Substances
Physiological Effects of Drugs

Meningoencephalitis
Nervous System Diseases
Growth Inhibitors
Angiogenesis Modulating Agents
Angiogenesis Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009